Search

Reduced serum magnesium concentrations in women with breast cancer compromises one of the antioxidant defense system involved in the carcinogenesis process. To evaluate parameters of magnesium, the enzyme activity of superoxide dismutase, and its relation with oxidative stress markers in women with breast cancer. A case-control study was conducted, involving 60 women in the age range between 29 and 65 years, divided into two groups: women with breast cancer (n = 30) and women without breast cancer (n = 30). Plasma; ionized, erythrocytic, and urinary magnesium intake; plasma concentrations of thiobarbituric acid reactive substances; and erythrocyte superoxide dismutase enzyme activity were evaluated. The mean value of the amount of dietary magnesium was below the recommended level in both groups studied, with no statistical difference (p > 0.05). Plasma, ionized, and erythrocyte magnesium concentrations of women with breast cancer were reduced in relation to the control group (p < 0.0001) and inadequate according to the reference values. Urinary excretion was high, with a significant difference between groups (p < 0.0001). The mean concentration of thiobarbituric acid reactive substances was high in the study participants, with no significant statistical difference between the groups (p > 0.05). The mean values of superoxide dismutase enzyme activity were adequate, with no statistically significant difference between the groups (p > 0.05). Women with breast cancer have impaired magnesium homeostasis, characterized by its reduction in diet, plasma, and erythrocytes and its increase in urine., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.)

Objectives: Recent studies have demonstrated that minerals play a role in glucose metabolism disorders in humans. Magnesium, in particular, is an extensively studied mineral that has been shown to function in the management of hyperglycemia, hyperinsulinemia, and insulin resistance (IR) action. The aim of this study was to investigate the effect of magnesium supplementation on IR in humans via systematic review of the available clinical trials., Methods: This review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. A survey was conducted to select clinical trials related to the effects of this mineral in insulin sensitivity using the following databases: PubMed, SciVerse Scopus, ScienceDirect, and SciVerse Cochrane., Results: After the selection process, 12 articles were identified as eligible, representing different clinical conditions and being free of restriction with regard to sex, age, ethnicity, and differential dosing/shape of magnesium. The results of eight clinical trials showed that supplementation with magnesium influences serum fasting glucose concentrations, and five trials determined an effect on fasting insulin levels. The results of seven studies demonstrated that mineral supplementation reduced homeostasis model assessment for IR values., Conclusions: The data of this systematic review provide evidence as to the benefits of magnesium supplementation in reducing IR in patients with hypomagnesemia presenting IR. However, new intervention studies are needed to elucidate the role of the nutrient in protection against this metabolic disorder, as well as the standardization of the type, dose, and time of magnesium supplementation., (Copyright © 2017 Elsevier Inc. All rights reserved.)

The present study evaluated the influence of magnesium on insulin resistance in obese women. A case-control study involving 114 women on the age between 20 and 50 years old, divided into two groups: control (eutrophic women, n = 59) and case (obese women, n = 55). The analysis of magnesium intake was carried out through the 3-day food record and also NutWin software version 1.5. The plasma, erythrocyte, and urinary magnesium concentrations were determined by flame atomic absorption spectrophotometry. The determinations of serum glucose and serum insulin were performed by enzymatic colorimetric method and chemiluminescence, respectively. The insulin resistance was assessed by homeostasis model assessment insulin resistance (HOMA-IR). The mean values of magnesium intake were lower than those recommended, without difference between groups (p > 0.05). All the patients who were evaluated showed adequate mean concentrations of magnesium in the plasma and erythrocyte. The urinary excretion of this mineral was lower than the reference values in both groups and did not show significant difference (p > 0.05). The values of serum glucose, serum insulin, and HOMA-IR were higher in obese women compared to the control group. A negative correlation was observed between erythrocyte magnesium and glycemic parameters (p < 0.05). Obese patients take in foods with low dietary magnesium content, and they show hypomagnesuria as a compensatory mechanism to keep the plasma concentration of this mineral in adequate levels. The correlation between the erythrocyte magnesium concentration and the parameters of glycemic control suggests the influence of this mineral on the index of insulin resistance in obese women.